References
- Thompson JF, Scolyer RA, Kefford RF. Cutaneous melanoma. Lancet 2005; 365:687–701; PMID: 15721476; http://dx.doi.org/10.1016/S0140-6736(05)17951-3
- Held MA, Langdon CG, Platt JT, Graham-Steed T, Liu Z, Chakraborty A, Bacchiocchi A, Koo A, Haskins JW, Bosenberg MW, et al. Genotype-selective combination therapies for melanoma identified by high-throughput drug screening. CancerDiscov 2013; 3:52–67; PMID: 23239741; http://dx.doi.org/10.1158/2159-8290.CD-12-0408
- Al-Lazikani B, Workman P. Unpicking the combination lock for mutant BRAF and RAS melanomas. CancerDiscov 2013; 3:14–9; PMID: 23319765; http://dx.doi.org/10.1158/2159-8290.CD-12-0520
- Alex J. Eustace SK, Anne-Marie Larkin, Thamir Mahgoub, Dimitrios Tryfonopoulos LOD, Martin Clynes, John Crown, O'Donovan N. Predictive biomarkers for dasatinib treatment in melanoma. Oncoscience 2014; 1:158–66
- Zbytek B, Carlson JA, Granese J, Ross J, Mihm MC, Jr., Slominski A. Current concepts of metastasis in melanoma. Expert RevDermatol 2008; 3:569–85; PMID: 19649148; http://dx.doi.org/10.1586/17469872.3.5.569
- Alitalo K, Carmeliet P. Molecular mechanisms of lymphangiogenesis in health and disease. CancerCell 2002; 1:219–27; PMID: 12086857; http://dx.doi.org/10.1016/S1535-6108(02)00051-X
- Tammela T, Zarkada G, Wallgard E, Murtomaki A, Suchting S, Wirzenius M, Waltari M, Hellstrom M, Schomber T, Peltonen R, et al. Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation. Nature 2008; 454:656–60; PMID: 18594512; http://dx.doi.org/10.1038/nature07083
- Smith NR, Baker D, James NH, Ratcliffe K, Jenkins M, Ashton SE, Sproat G, Swann R, Gray N, Ryan A, et al. Vascular endothelial growth factor receptors VEGFR-2 and VEGFR-3 are localized primarily to the vasculature in human primary solid cancers. Clin CancerRes 2010; 16:3548–61; PMID: 20606037; http://dx.doi.org/10.1158/1078-0432.CCR-09-2797
- Clarijs R, Schalkwijk L, Hofmann UB, Ruiter DJ, de Waal RM. Induction of vascular endothelial growth factor receptor-3 expression on tumor microvasculature as a new progression marker in human cutaneous melanoma. CancerRes 2002; 62:7059–65; PMID: 12460927
- Emmett MS, Symonds KE, Rigby H, Cook MG, Price R, Metcalfe C, Orlando A, Bates DO. Prediction of melanoma metastasis by the Shields index based on lymphatic vessel density. BMCCancer 2010; 10:208; PMID: 20478045; http://dx.doi.org/10.1186/1471-2407-10-208
- Hoshida T, Isaka N, Hagendoorn J, di Tomaso E, Chen YL, Pytowski B, Fukumura D, Padera TP, Jain RK. Imaging steps of lymphatic metastasis reveals that vascular endothelial growth factor-C increases metastasis by increasing delivery of cancer cells to lymph nodes: therapeutic implications. CancerRes 2006; 66:8065–75; PMID: 16912183; http://dx.doi.org/10.1158/0008-5472.CAN-06-1392
- Bogos K, Renyi-Vamos F, Dobos J, Kenessey I, Tovari J, Timar J, Strausz J, Ostoros G, Klepetko W, Ankersmit HJ, et al. High VEGFR-3-positive circulating lymphatic/vascular endothelial progenitor cell level is associated with poor prognosis in human small cell lung cancer. Clin CancerRes 2009; 15:1741–6; PMID: 19240177; http://dx.doi.org/10.1158/1078-0432.CCR-08-1372
- Mehnert JM, McCarthy MM, Jilaveanu L, Flaherty KT, Aziz S, Camp RL, Rimm DL, Kluger HM. Quantitative expression of VEGF, VEGF-R1, VEGF-R2, and VEGF-R3 in melanoma tissue microarrays. HumPathol 2010; 41:375–84; PMID: 20004943; http://dx.doi.org/10.1016/j.humpath.2009.08.016
- Roberts N, Kloos B, Cassella M, Podgrabinska S, Persaud K, Wu Y, Pytowski B, Skobe M. Inhibition of VEGFR-3 activation with the antagonistic antibody more potently suppresses lymph node and distant metastases than inactivation of VEGFR-2. CancerRes 2006; 66:2650–7; PMID: 16510584; http://dx.doi.org/10.1158/0008-5472.CAN-05-1843
- Alam A, Blanc I, Gueguen-Dorbes G, Duclos O, Bonnin J, Barron P, Laplace MC, Morin G, Gaujarengues F, Dol F, et al. SAR131675, a potent and selective VEGFR-3-TK inhibitor with antilymphangiogenic, antitumoral, and antimetastatic activities. Mol CancerTher 2012; 11:1637–49; PMID: 22584122; http://dx.doi.org/10.1158/1535-7163.MCT-11-0866-T
- Norrmen C, Tammela T, Petrova TV, Alitalo K. Biological basis of therapeutic lymphangiogenesis. Circulation 2011; 123:1335–51; PMID: 21444892; http://dx.doi.org/10.1161/CIRCULATIONAHA.107.704098
- Smalley KSM, Haass NK, Brafford PA, Lioni M, Flaherty KT, Herlyn M. Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases. Mol CancerTherap 2006; 5:1136–44; PMID: 16731745; http://dx.doi.org/10.1158/1535-7163.MCT-06-0084
- Garces CA, Kurenova EV, Golubovskaya VM, Cance WG. Vascular endothelial growth factor receptor-3 and focal adhesion kinase bind and suppress apoptosis in breast cancer cells. CancerRes 2006; 66:1446–54; PMID: 16452200; http://dx.doi.org/10.1158/0008-5472.CAN-05-1661
- Cox BD, Natarajan M, Stettner MR, Gladson CL. New concepts regarding focal adhesion kinase promotion of cell migration and proliferation. J CellBiochem 2006; 99:35–52; PMID: 16823799; http://dx.doi.org/10.1002/jcb.20956
- Lechertier T, Hodivala-Dilke K. Focal adhesion kinase and tumour angiogenesis. JPathol 2012; 226:404–12; PMID: 21984450; http://dx.doi.org/10.1002/path.3018
- Zhao X, Guan J-L. Focal adhesion kinase and its signaling pathways in cell migration and angiogenesis. Adv Drug DeliverRev 2011; 63:610–5; PMID: 21118706; http://dx.doi.org/10.1016/j.addr.2010.11.001
- Tavora B, Batista S, Reynolds LE, Jadeja S, Robinson S, Kostourou V, Hart I, Fruttiger M, Parsons M, Hodivala-Dilke KM. Endothelial FAK is required for tumour angiogenesis. EMBO MolMed 2010; 2:516–28; PMID: 21154724; http://dx.doi.org/10.1002/emmm.201000106
- Wary KK, Kohler EE, Chatterjee I. Focal adhesion kinase regulation of neovascularization. MicrovascRes 2012; 83:64–70; PMID: 21616084; http://dx.doi.org/10.1016/j.mvr.2011.05.002
- Kurenova EV, Hunt DL, He D, Magis AT, Ostrov DA, Cance WG. Small molecule chloropyramine hydrochloride (C4) targets the binding site of focal adhesion kinase and vascular endothelial growth factor receptor 3 and suppresses breast cancer growth in vivo. J MedChem 2009; 52:4716–24; PMID: 19610651; http://dx.doi.org/10.1021/jm900159g
- Smith CS, Golubovskaya VM, Peck E, Xu LH, Monia BP, Yang X, Cance WG. Effect of focal adhesion kinase (FAK) downregulation with FAK antisense oligonucleotides and 5-fluorouracil on the viability of melanoma cell lines. MelanomaRes 2005; 15:357–62; PMID: 16179862; http://dx.doi.org/10.1097/00008390-200510000-00003
- Guedez L, Rivera AM, Salloum R, Miller ML, Diegmueller JJ, Bungay PM, Stetler-Stevenson WG. Quantitative assessment of angiogenic responses by the directed in vivo angiogenesis assay. Am JPathol 2003; 162:1431–9; PMID: 12707026; http://dx.doi.org/10.1016/S0002-9440(10)64276-9
- Frisch SM, Schaller M, Cieply B. Mechanisms that link the oncogenic epithelial–mesenchymal transition to suppression of anoikis. J CellSci 2013; 126:21–9; PMID: 23516327; http://dx.doi.org/10.1242/jcs.120907
- Schultze A, Fiedler W. Therapeutic potential and limitations of new FAK inhibitors in the treatment of cancer. Expert Opin InvestDrugs 2010; 19:777–88; PMID: 20465362; http://dx.doi.org/10.1517/13543784.2010.489548
- Ward KK, Tancioni I, Lawson C, Miller NL, Jean C, Chen XL, Uryu S, Kim J, Tarin D, Stupack DG, et al. Inhibition of focal adhesion kinase (FAK) activity prevents anchorage-independent ovarian carcinoma cell growth and tumor progression. Clin ExpMetastasis 2013; 30:579–94; PMID: 23275034; http://dx.doi.org/10.1007/s10585-012-9562-5
- Infante JR, Camidge DR, Mileshkin LR, Chen EX, Hicks RJ, Rischin D, Fingert H, Pierce KJ, Xu H, Roberts WG, et al. Safety, pharmacokinetic, and pharmacodynamic phase I dose-escalation trial of PF-00562271, an inhibitor of focal adhesion kinase, in advanced solid tumors. J ClinOncol 2012; 30:1527–33; PMID: 22454420; http://dx.doi.org/10.1200/JCO.2011.38.9346
- Schultze A, Fiedler W. Clinical importance and potential use of small molecule inhibitors of focal adhesion kinase. Anticancer Agents MedChem 2011; 11:593–9; PMID: 21787277; http://dx.doi.org/10.2174/187152011796817727
- Cance WG, Kurenova E, Marlowe T, Golubovskaya V. Disrupting the scaffold to improve focal adhesion kinase-targeted cancer therapeutics. SciSignal 2013; 6:10–15; http://dx.doi.org/10.1126/scisignal.2004021
- Akasaka T, van Leeuwen RL, Yoshinaga IG, Mihm MC, Jr., Byers HR. Focal adhesion kinase (p125FAK) expression correlates with motility of human melanoma cell lines. J InvestDermatol 1995; 105:104–8; PMID: 7615962; http://dx.doi.org/10.1111/1523-1747.ep12313396
- Xu LH, Yang X, Craven RJ, Cance WG. The COOH-terminal domain of the focal adhesion kinase induces loss of adhesion and cell death in human tumor cells. Cell GrowthDiffer 1998; 9:999–1005; PMID: 9869300
- Abdel-Ghany M, Cheng HC, Elble RC, Pauli BU. Focal adhesion kinase activated by beta(4) integrin ligation to mCLCA1 mediates early metastatic growth J BiolChem 2002; 277:34391–400; PMID: 12110680; http://dx.doi.org/10.1074/jbc.M205307200
- Hess AR, Postovit LM, Margaryan NV, Seftor EA, Schneider GB, Seftor RE, Nickoloff BJ, Hendrix MJ. Focal adhesion kinase promotes the aggressive melanoma phenotype. CancerRes 2005; 65:9851–60; PMID: 16267008; http://dx.doi.org/10.1158/0008-5472.CAN-05-2172
- Hess AR, Hendrix MJ. Focal adhesion kinase signaling and the aggressive melanoma phenotype. CellCycle 2006; 5:478–80; PMID: 16552181; http://dx.doi.org/10.4161/cc.5.5.2518
- Abbi S, Guan JL. Focal adhesion kinase: protein interactions and cellular functions. HistolHistopathol 2002; 17:1163–71; PMID: 12371144
- Fan H, Zhao X, Sun S, Luo M, Guan J-L. Focal adhesion kinase scaffolding function to mediate endophilin A2 phosphorylation promotes epithelial-mesenchymal transition and mammary cancer stem cell activities in vivo. J BiolChem 2013; 288: 3322-33; PMID: 23255596; http://dx.doi.org/10.1074/jbc.M112.420497
- Kaneda T, Sonoda Y, Ando K, Suzuki T, Sasaki Y, Oshio T, Tago M, Kasahara T. Mutation of Y925F in focal adhesion kinase (FAK) suppresses melanoma cell proliferation and metastasis. CancerLett 2008; 270:354–61; PMID: 18606490; http://dx.doi.org/10.1016/j.canlet.2008.05.042
- Cohen C, Zavala-Pompa A, Sequeira JH, Shoji M, Sexton DG, Cotsonis G, Cerimele F, Govindarajan B, Macaron N, Arbiser JL. Mitogen-actived protein kinase activation is an early event in melanoma progression. Clin CancerRes 2002; 8:3728–33; PMID: 12473582
- Salameh A, Galvagni F, Bardelli M, Bussolino F, Oliviero S. Direct recruitment of CRK and GRB2 to VEGFR-3 induces proliferation, migration, and survival of endothelial cells through the activation of ERK, AKT, and JNK pathways. Blood 2005; 106:3423–31; PMID: 16076871; http://dx.doi.org/10.1182/blood-2005-04-1388
- Mitra SK, Mikolon D, Molina JE, Hsia DA, Hanson DA, Chi A, Lim ST, Bernard-Trifilo JA, Ilic D, Stupack DG, et al. Intrinsic FAK activity and Y925 phosphorylation facilitate an angiogenic switch in tumors. Oncogene 2006; 25: 5969–84; PMID: 16682956
- Streit M, Detmar M. Angiogenesis, lymphangiogenesis, and melanoma metastasis. Oncogene 2003; 22:3172–9; PMID: 12789293; http://dx.doi.org/10.1038/sj.onc.1206457
- Schicher N, Paulitschke V, Swoboda A, Kunstfeld R, Loewe R, Pilarski P, Pehamberger H, Hoeller C. Erlotinib and Bevacizumab Have Synergistic Activity against Melanoma. Clin CancerRes 2009; 15:3495–502; PMID: 19447871; http://dx.doi.org/10.1158/1078-0432.CCR-08-2407
- Zhang XH, Qiao EQ, Gao Z, Yuan HQ, Cai PF, Li XM, Gu YH. Efficacy of combined axitinib with dacarbazine in a B16F1 melanoma xenograft model. OncolLett 2013; 6:69–74; PMID: 23946779
- Helfrich I, Scheffrahn I, Bartling S, Weis J, von Felbert V, Middleton M, Kato M, Ergün S, Augustin HG, Schadendorf D. Resistance to antiangiogenic therapy is directed by vascular phenotype, vessel stabilization, and maturation in malignant melanoma. J ExpMed 2010; 207:491–503; PMID: 20194633; http://dx.doi.org/10.1084/jem.20091846
- Haskell H, Natarajan M, Hecker TP, Ding Q, Stewart J, Grammer JR, Gladson CL. Focal adhesion kinase is expressed in the angiogenic blood vessels of malignant astrocytic tumors in vivo and promotes capillary tube formation of brain microvascular endothelial cells. Clin CancerRes 2003; 9:2157–65; PMID: 12796381
- Chou T-C. Drug combination studies and their synergy quantification using the chou-talalay method. CancerRes 2010; 70:440–6; PMID: 20068163; http://dx.doi.org/10.1158/0008-5472.CAN-09-1947
- Seshadri M, Sacadura N, Coulthard T. Monitoring antivascular therapy in head and neck cancer xenografts using contrast-enhanced MR and US imaging. Angiogenesis 2011; 14:491–501; PMID: 21901534; http://dx.doi.org/10.1007/s10456-011-9233-1
- Sunar U, Rohrbach D, Rigual N, Tracy E, Keymel K, Cooper MT, Baumann H, Henderson BH. Monitoring photobleaching and hemodynamic responses to HPPH-mediated photodynamic therapy of head and neck cancer: a case report. OptExpress 2010; 18:14969–78; PMID: 20639983; http://dx.doi.org/10.1364/OE.18.014969
- Ucar DA, Kurenova E, Garrett TJ, Cance WG, Nyberg C, Cox A, Massoll N, Ostrov DA, Lawrence N, Sebti SM, et al. Disruption of the protein interaction between FAK and IGF-1R inhibits melanoma tumor growth. CellCycle 2012; 11:3250–9; PMID: 22894899; http://dx.doi.org/10.4161/cc.21611